Stockscreener 앱 받기
27.50
4.65%
-1.34
시간 외 거래:
27.65
0.15
+0.55%
전일 마감가:
$28.84
열려 있는:
$28.895
하루 거래량:
32,914
Relative Volume:
0.61
시가총액:
$1.21B
수익:
$9.74M
순이익/손실:
$7.19M
주가수익비율:
167.99
EPS:
0.1637
순현금흐름:
$2.25M
1주 성능:
+2.08%
1개월 성능:
+34.08%
6개월 성능:
-10.71%
1년 성능:
+331.03%
1일 변동 폭
$26.00
$29.02
1주일 범위
$25.50
$29.95
52주 변동 폭
$6.05
$55.65
Anbio Biotechnology Stock (NNNN) Company Profile
Compare NNNN vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
27.50 | 1.27B | 9.74M | 7.19M | 2.25M | 0.1637 |
ISRG
Intuitive Surgical Inc
|
468.36 | 165.94B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.52 | 44.30B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
80.73 | 38.96B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
47.93 | 38.69B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
228.80 | 33.61B | 5.40B | 1.49B | 1.78B | 10.12 |
Anbio Biotechnology 주식(NNNN)의 최신 뉴스
Why Anbio Biotechnology Shares Are Sliding Fast - TipRanks
Assessing Anbio Biotechnology (NNNN) Valuation After Sharp Swings And A Rich Price To Book Multiple - simplywall.st
Anbio Biotechnology Broadens Test Portfolio And Shifts Risk Profile - Sahm
Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio - Sahm
Anbio Biotechnology posts solid FY25 results, diversifies portfolio - MSN
Form 20-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] - ADVFN
Discovering US Undiscovered Gems for April 2026 - simplywall.st
Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer - Stock Titan
Anbio Biotechnology (ANBF) Non Cash 74.1% Net Margin Fuels Fresh Debate On Earnings Quality - Sahm
Anbio Biotechnology | 3: Initial statement of beneficial ownership of securities- Hartzler Nancy - Moomoo
Anbio Biotechnology (NNNN) CEO Michael Lau identified as insider in Form 3 - Stock Titan
Anbio Biotechnology (NNNN) director XU CANY files initial Form 3 - Stock Titan
Why Anbio Biotechnology Class A Shares Are Sinking - TipRanks
Super-voting control and post-COVID shift at Anbio Biotechnology (Nasdaq: NNNN) - Stock Titan
Anbio Biotechnology Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Exxon Mobil, Pepsico among market cap stock movers on Monday - Investing.com UK
Exxon Mobil, Pepsico among market cap stock movers on Monday By Investing.com - Investing.com Canada
Anbio Biotechnology (NNNN) Surges 11.6% Intraday – What’s Fueling the Volatility? - Bitget
Why Anbio Biotechnology Class A Shares Are Surging - TipRanks
Why Anbio Biotechnology Class A Shares Are Jumping - TipRanks
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum - The Manila Times
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum on March 17, 2026 - geneonline.com
Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review - Defense World
Anbio Biotechnology and Oncocyte Compared in Financial Analysis - National Today
Anbio Biotechnology falls -5.8% - MSN
Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Anbio Biotechnology Stock Quote, Share Price, News and Analysis - Longbridge
Head to Head Contrast: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Critical Comparison - Defense World
TechTarget (TTGT) to Release Earnings on Wednesday - Defense World
Anbio Biotechnology: Improved Margins, Still Priced For Growth That Isn't Showing Up - Seeking Alpha
NNNN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head to Head Contrast - Defense World
NNNN Technical Analysis & Stock Price Forecast - Intellectia AI
Anbio Biotechnology Outperforms Oncocyte in Financial Metrics - National Today
Anbio Biotechnology (NNNN) Stock Analysis: Navigating Volatility in the Medical Instruments Sector - DirectorsTalk Interviews
Critical Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Anbio Biotechnology Outperforms Oncocyte in Head-to-Head Review - National Today
Celestica Inc. (TSE:CLS) Receives Average Recommendation of “Strong Buy” from Analysts - Defense World
Comparing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX) - Defense World
Financial Contrast: Oncocyte and Anbio Biotechnology - National Today
Head-To-Head Survey: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) - Defense World
Reviewing Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) - Defense World
Diane Lazzaris Sells 2,747 Shares of WESCO International (NYSE:WCC) Stock - Defense World
Anbio Biotechnology and Oncocyte Compared: Which Stock Reigns Supreme? - National Today
Anbio Biotechnology (NNNN) Stock Analysis: What Investors Should Know About This German IVD Innovator - DirectorsTalk Interviews
Anbio Biotechnology prices $8M IPO at $5 per share - MSN
Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN) Critical Comparison - Defense World
Anbio Biotechnology (NNNN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
1.84%
자본화:
|
볼륨(24시간):